Loading organizations...
§ Private Profile · Daejeon, Taejon-jikhalsi, South Korea
AI-driven biotechnology platform accelerating drug discovery for rare and intractable diseases, focusing on small molecule precision medicines.
Based in Seoul, South Korea, Deargen is an artificial intelligence-driven biotechnology platform that accelerates drug discovery for rare and intractable diseases by analyzing genome data and optimizing molecular candidates. The company utilizes proprietary computational technologies, including its Dr. UG, DearTRANS, and MolEQ systems, to identify novel disease targets and support the development of small molecule precision medicines. Operating within the genomics and life sciences sectors, the firm focuses on reducing the time and cost associated with traditional pharmaceutical research. To scale its research and development operations, the enterprise has raised $17 million in total equity funding, culminating in a Series B financing round in February 2022. This capital was secured from a syndicate of institutional backers that includes the Korean Development Bank, Nvester, and The Wells Investment. Deargen was founded in 2016 by Gilsu Kang.
Deargen has raised $17.0M across 1 funding round.
Deargen has raised $17.0M in total across 1 funding round.
Deargen has raised $17.0M across 1 funding round. Most recently, it raised $17.0M Series B in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 24, 2022 | $17M Series B | — | Hana Ventures, Korea Development Bank, Hyungsoon Chun, Junwoo Park | Announced |
Deargen has raised $17.0M in total across 1 funding round.
Deargen's investors include Hana Ventures, Korea Development Bank, Hyungsoon Chun, Junwoo Park.